Abstract: Recent data suggests the presence of cytotoxic (TIA-1 and granzyme B+ ) and regulatory T-cells (FOXP3+) in classical Hodgkin lymphoma (cHL) tissues has been shown to correlate with poor overall survival in mainly diagnostic biopsies. By tissue microarray analyses, we extend this observation to a cohort of relapsed/refractory cHL tissue biopsies and analyze immunohistochemical expression of FOXP3, TIA-1, and granzyme B in the inflammatory background and the tumor microenvironment. High expression of TIA-1 (>50%) correlated with poor overall survival (P<0.0001), low expression of FOXP3 (<25%) correlated with poor overall survival (P<0.01), and combined high TIA-1 (>50%) and low FOXP3 (<25%) correlated with poor overall survival (P<0.0001). Expression of cytotoxic and regulatory T-cells shows prognostic significance in the relapsed/refractory clinical setting of cHL.
I
n histologic sections of Hodgkin lymphoma (HL), neoplastic cells constitute <1% of the total cell population with a pronounced reactive inflammatory background. Regulatory T-cells within the inflammatory background may play a role in the antitumor hostimmune response and the role of tumor microenvironment is of interest. [1] [2] [3] [4] The prognostic role of cytotoxic T-cell markers in classical HL (cHL) has been shown as well as the role of chemokines in attracting cytotoxic and regulatory T-cells. 5 Although earlier data suggested no prognostic significance to TIA-1 expression alone in cHL, 6 recent data show correlation between the presence of cytotoxic (TIA-1+ and granzyme B+) and regulatory T-cells (FOXP3+) and poor overall survival (OS), [7] [8] [9] however, one report studied only 4 cases of relapsed biopsies. 7 The use of tissue microarrays (TMAs) has been used in the study of cHL [10] [11] [12] and we were therefore interested in analyzing expression of these markers for specific cell types in the inflammatory background in a larger series of relapsed/refractory cHL biopsies to determine whether there was any correlation with clinical factors and survival outcome.
MATERIALS AND METHODS
Cases of relapsed/refractory cHL were consecutively ascertained from the files of Memorial Sloan-Kettering Cancer Center (MSKCC) and use of tissues was approved by the Institution's Human Biospecimen Utilization Committee and an Institutional Research Board waiver. Patients were treated on one of 3 sequential Institutional Research Board-approved clinical trials of high dose therapy/autologous stem cell transplant at MSKCC between October 1994 and September 2003 that required biopsy confirmation of relapsed/refractory HL. Clinical characteristics of patients with relapsed HL who underwent autologous transplantation on 2 sequential prospective studies and data on histologic subtypes are summarized in Table 1 . The cohort comprised of a total of 63 patients, 22 females and 41 males. The median age was 29 years (range from 17 to 62 y). Clinical outcomes have already been reported as noted above. 13, 14 A TMA of the reactive inflammatory background of relapsed/refractory cHL cases was constructed using a fully automated arrayer Beecher instrument, ATA-27. TMAs were stained in the Pathology Core Immunohistochemistry Laboratory at MSKCC using the following conditions: FOXP3, a monoclonal antibody (MAB) from ABCAM Inc (Cambridge, MA) used pretreatment steaming with ethylenediaminetetraacetic acid pH 8.0 for 30 minutes with a 1:1000 dilution of the primary antibody overnight incubation at 41C, a secondary antimouse from Vector Labs (Burlingame, CA) for 1 hour, Streptavidin from DAKO (Carpenteria, CA) at 1:500 dilution for 1 hour, and diaminobenzidine for 5 minutes. TIA-1, MAB, at a 1:400 dilution from Immunotech Inc (Beckman Coulter, Miami, FL) performed on the Ventana Discovery XT (Tuscon, AZ). Granzyme B, a MAB, from ABCAM Inc (Cambridge, MA) was used at a 1:10 dilution and performed on Ventana Discovery XT (Tuscon, AZ). Stained TMA slides were evaluated by 2 pathologists (A.F.K. and J.T.F.) using the Olympus BX41 double-headed microscope using 20 Â /0.50 and/or 40 Â /0.75 objectives, and scored using the following criteria: 0 = negative; 1+ = <25%; 2+ = 25% to 50%; 3+ = 50% to 75%; and 4+ = >75%. A total of 63 evaluable cases of relapsed/refractory cHL with tissue core availability and stain results for TIA-1, granzyme B, and FOXP3 were obtained. Results were linked with clinical factors and statistically analyzed using SPSS v15.0 and SAS software. Clinical characteristics included age at autologous stem cell transplant, presence of bulky disease >10 cm, presence of B symptoms, high risk factors, number of involved sites, disease progression, and survival. Histologic features were reviewed; all cases were diagnosed as cHL according to the World Health Organization classification scheme. Histologic subtype (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) was noted and presence of CD20 positivity of Reed-Sternberg cells. Radiologic status including positron emission tomography scan after ifosfamide, carboplatin and etoposide chemotherapy was also noted. Histologic and immunohistochemical images for Figures 1 to 4 were obtained with the Olympus AH2 microscope Camera from Center Valley, Pennsylvania. Image acquisition and processing software was performed using Adobe Photoshop 7.0 and Olympus DP12 software. Survival analysis was performed using failure-free survival and OS as clinical end points and plotted as Kaplan-Meier survival curves. Statistical analysis was performed using SPSS version 12.0 (SPSS Inc, Chicago, IL).
RESULTS
The TMA scores for TIA-1, FOXP3, and granzyme B are summarized in Table 2 . Representative hematoxylin and eosin sections of cHL cases that showed an increase in TIA-1+ cells and decrease of FOXP3+ cells are shown in Figure 1 . Representative images and examples of 1+, 2+, 3+, and 4+ staining for TIA-1 from the immunohistochemical stained TMA slide are shown in Figure 2 . Representative images of high and low staining for granzyme B from the immunohistochemical-stained TMA slide are shown in Figure 3 . The inflammatory cells showed characteristic cytoplasmic granular staining and localization for TIA-1 and granzyme B. TIA-1 was noted to show localization to myeloid and neutrophil cells as well as lymphoid cells, whereas granzyme B was noted to be localized to lymphoid cells only, presumably cytotoxic T-cells. The extent of reactivity for granzyme B (89% with score of 1) was far less than that observed for TIA-1 (82% with score of 2 or greater). Cases with predominant myeloid and neutrophil cytoplasmic localization of TIA-1 could account for differences in reactivity between granzyme B seen localized in general to lymphoid cells, presumably cytotoxic T-cells. The remote possibility of technical artifact in staining technique cannot also be ruled out. Representative images and examples of FOXP3 scored as 1+, 2+, and 3+ from the immunohistochemical-stained TMA slide are shown in Figure 4 with the inflammatory cells showing nuclear localization. TIA-1 staining showed significant inverse correlation with FOXP3 in relapsed/refractory biopsies (P<0.0002). No significant correlation was seen with granzyme B expression, high lactate dehydrogenase, and relapse in prior radiation site. High expression of TIA-1 (>50%) correlated with poor OS (P<0.0001) as shown in Figure 5A , low expression of FOXP3 (<25%) correlated with poor OS (P<0.01) as seen Figure 5B , and combined high TIA-1 (>50%) and low FOXP3 (<25%) correlated with poor OS (P<0.0001) as shown in Figure 5C . This study confirms the observation of increased TIA-1, a marker of cytotoxic T cells (abbreviated as TIA-1 throughout the remainder of the discussion) and decreased FOXP3, a marker of regulatory T-cells (abbreviated as FOXP3 throughout the remainder of the discussion) correlates with a poor outcome in a larger series of relapsed/refractory cHL biopsies. This observation was previously reported mainly in diagnostic specimens of cHL, [7] [8] [9] with one report analyzing only 4 cases of relapsed biopsies. 7 Our data also confirms that high FOXP3, a marker of regulatory T-cells, suggests better OS as indicated in a series of diagnostic specimens of cHL. 9 Recent gene expression profiling and correlative immunohistochemistry expression on tissue also show that high TIA-1 expression was associated with poor or adverse survival and a high FOXP3 correlated with a favorable influence. 15 Schreck et al 16 showed that a high frequency of tumor-infiltrating c-Maf (Th2) cells was associated with an improved disease and event-free survivals. They also showed that a high ratio of FOXP3 (Treg) over c-Maf (Th2) cells resulted in a shortened disease-free survival. Although they do not report on the prognosis of FOXP3 alone, their data indirectly implies a high FOXP3 may correlate with a favorable response. The recruitment of Tregs to tumors is poorly understood, but might involve chemokines. 17 Some data suggest that an increase of Tregs is associated with loss of EpsteinBarr virus (EBV) immunity and that Epstein-Barr virus nuclear antigen 1 up-regulates the expression CCL20 in HL cells and that this leads to increased chemotaxis of Tregs. 18 Earlier studies have not found any association with EBV infection and the proportion of FOXP3 and TIA-1 positivity 7 or a survival difference between EBVpositive and negative patients although data is controversial in the literature. 8 Recent data suggest Hodgkin and Reed-Sternberg cells express interleukin-21 which upregulates macrophage inflammatory protein-3a which in turn attracts CCR6+CD4+CD25+FoxP3+CD127lo regulatory T-cells toward Hodgkin and Reed-Sternberg cells, which might favor their immune escape.
19 Gal1 treatment of activated T-cells favored the secretion of Th2 cytokines and the expansion of CD4+CD25high-FOXP3+ Treg cells, therefore, Gal1 may represent a potential therapeutic target for restoring immune surveillance in cHL. 20 The increase of Treg cells seems to be a characteristic feature in most tumors, with much recent interest in the molecular and cellular mechanisms responsible for the increase and maintenance of elevated levels of Treg cells in cancer and as a potential therapeutic agent, so much so, with an entire May issue of Immunity devoted to the subject. [21] [22] [23] [24] [25] [26] [27] [28] Further insights into the molecular mechanisms and association with other signaling pathways and relation with EBV will be of interest in the clinicopathologic significance in HL and provide additional insight into novel therapeutic strategies. Figure 5A , low expression of FOXP3 (<25%) correlated with poor overall survival (P<0.01) as seen Figure 5B , and combined high TIA-1 (>50%) low FOXP3 (<25%) correlated with poor overall survival (P<0.0001) shown in Figure 5C . 
